Exelixis, INC Form 4 insider transactions

Exelixis' EVP of Research and Development, Dana Aftab, reported the sale of 29,873 shares of common stock for approximately $1.325 million.

Exelixis Director Jack L. Wyszomierski exercised options and subsequently sold a significant number of common shares under a pre-arranged trading plan.

Exelixis Director Julie Smith exercised stock options and subsequently sold a significant number of common shares in mid-February 2026.

Exelixis EVP and CFO Christopher J. Senner reported sales of common stock and shares withheld for taxes totaling 100,765 shares under a pre-arranged 10b5-1 trading plan.

Exelixis EVP of Commercial, Patrick J. Haley, reported the sale of common stock following the vesting of performance-based restricted stock units.

Exelixis President and CEO Michael Morrissey reported a series of transactions including option exercises, tax-related share disposals, and gifts to a family trust.

EXELIXIS Director Sue Gail Eckhardt sold 3,856 shares of common stock for $43.79 per share under a pre-arranged Rule 10b5-1 trading plan.

Exelixis, Inc.'s EVP of Research and Development, Dana Aftab, reported the withholding of 39,205 shares of common stock to cover tax obligations related to vested restricted stock units.

Exelixis Director Bob Oliver exercised options and subsequently sold a portion of his common stock holdings.

Exelixis's SVP and General Counsel, Brenda Hefti, reported the sale of 18,669 shares of common stock and the withholding of 5,430 shares for tax obligations.

Exelixis, Inc. CEO Michael Morrissey reported the vesting of 548,073 performance-based restricted stock units and a tax-related disposition of 139,524 shares.

Exelixis EVP of Research and Development, Dana Aftab, vested 119,578 performance-based restricted stock units, with a portion withheld for taxes.

Exelixis EVP Patrick J. Haley vested 139,508 shares from a performance-based restricted stock unit award after the Compensation Committee certified performance criteria achievement.

Exelixis' Executive Vice President and CFO, Christopher J. Senner, vested 149,474 performance-based restricted stock units after the company achieved certain performance criteria.

Exelixis' SVP and General Counsel, Brenda Hefti, was granted 30,170 restricted stock units as part of the company's equity incentive plan.

EXELIXIS Director David Edward Johnson and Caligan Partners LP reported the purchase of 27,532 shares of common stock.

Exelixis EVP of Commercial, Patrick J. Haley, reported the sale of 72,230 shares of common stock across multiple transactions in late November 2025.

Exelixis EVP of Research and Development, Dana Aftab, gifted 24,000 shares of common stock to a donor-advised fund on November 21, 2025.

Exelixis Director Bob Oliver reported gifting 1,044 shares of common stock to a not-for-profit organization, maintaining significant beneficial ownership.

Exelixis Director Stelios Papadopoulos reported the sale of 100,000 common shares for approximately $4.35 million under a pre-arranged trading plan.

Exelixis President and CEO Michael Morrissey reported gifting 341,548 shares of common stock across multiple transactions in November 2025.

Exelixis' EVP of Research and Development, Dana Aftab, reported the pre-planned sale of 48,383 shares of common stock for approximately $2.06 million.

Exelixis Director Mary C. Beckerle exercised options and subsequently sold a total of 24,622 shares of common stock on November 11, 2025.

Exelixis's EVP of Research & Development, Dana Aftab, was granted 50,673 restricted stock units on October 8, 2025, under the company's equity incentive plan.

Exelixis, Inc. Director Sue Gail Eckhardt sold 18,838 shares of common stock on June 2, 2025, as part of a pre-established Rule 10b5-1 trading plan.

Director Jack L. Wyszomierski of Exelixis, Inc. sold 7,535 shares of common stock at an average price of $43.09 on June 3, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Exelixis, Inc. director David Edward Johnson was granted 21,464 stock options with an exercise price of $42.60, vesting fully on the first anniversary of the grant date.

Exelixis, Inc. Director Mary C. Beckerle was granted 9,812 restricted stock units (RSUs) on May 29, 2025, which will vest in May 2026.

Exelixis, Inc. Director Bob Oliver was granted 9,812 Restricted Stock Units (RSUs) on May 29, 2025, aligning his compensation with the company's long-term performance.

Exelixis, Inc. Director Tomas J. Heyman was granted 9,812 restricted stock units (RSUs) on May 29, 2025, which are set to vest fully on May 29, 2026.